RELEASED ON 09/04/13 (DD/MM/YY)
Roche will release study data on Tamiflu for independent analysis after it had long refused to provide all the available results for its antiviral drug, Reuters said citing an e-mail by the Swiss drug maker to researchers organisation Cochrane Collaboration.
The company has carried out 74 trials on the efficiency of Tamiflu but published only a small part of their results. Researchers have been seeking access to the full data for years suspecting that Roche withholds less positive results.
The Swiss drug maker now agreed to transfer all the data to British Medical Journal. The information is to be published in the next few months.
Roche has made revenue of about USD 12 billion (EUR 9.22bn) from Tamiflu since 2002. Cochrane Collaboration, which independently assesses benefits and side effects of therapies, doubted the efficacy of the drug already in 2009. The main question was whether Tamiflu can really prevent complications such as lung complications.
SOURCE SeeNews Switzerland
Roche will release study data on Tamiflu for independent analysis after it had long refused to provide all the available results for its antiviral drug, Reuters said citing an e-mail by the Swiss drug maker to researchers organisation Cochrane Collaboration.
The company has carried out 74 trials on the efficiency of Tamiflu but published only a small part of their results. Researchers have been seeking access to the full data for years suspecting that Roche withholds less positive results.
The Swiss drug maker now agreed to transfer all the data to British Medical Journal. The information is to be published in the next few months.
Roche has made revenue of about USD 12 billion (EUR 9.22bn) from Tamiflu since 2002. Cochrane Collaboration, which independently assesses benefits and side effects of therapies, doubted the efficacy of the drug already in 2009. The main question was whether Tamiflu can really prevent complications such as lung complications.
SOURCE SeeNews Switzerland